Alto Neuroscience Stock Surges on $120M Funding

Alto Neuroscience Secures $120M to Advance Depression Drug Trials

• Alto Neuroscience raised $120 million from institutional and accredited investors to fund ALTO-207, a treatment for treatment-resistant depression.
• The financing will support Phase 2b and Phase 3 clinical trials, with potential for a New Drug Application if successful.
• The funding round was led by Commodore Capital, with participation from Dellora Investments, Driehaus Capital Management, Perceptive Advisors, and others.
• Alto reported a net loss of around $63 million for 2025 but maintains a cash balance of $177 million to fund operations into 2028.
• The company plans to begin Phase 2b testing in early 2026 and a Phase 3 study in early 2027.

Alto Neuroscience’s stock rose approximately 7% in premarket trading following the announcement of their successful $120 million funding round aimed at advancing ALTO-207 trials.